What topics does this cannabis study cover?

This study covers research on: Endocannabinoid.

Where was this research published?

Published in Bioorganic & medicinal chemistry on October 2, 2026.

Lab tests support Pep-5 as a possible CB2 allosteric modulator

Q: What did this research study find?

In *in vitro* assays, **Pep-5 inhibited cAMP accumulation in a CB2-expression-dependent manner**, with an EC₅₀ of 6.0 μM.

Targeting the putative allosteric site J of cannabinoid receptor type 2 with peptide modulators: From mechanistic investigation to candidate identification.

Bioorganic & medicinal chemistry • October 2, 2026 • Highly Relevant

🤖

AI Summary

The study asked whether the extracellular putative site J on the CB2 cannabinoid receptor could serve as a binding site for peptide-based allosteric modulators. Researchers used molecular docking and dynamics simulations to model two previously known peptides, then screened 56 peptide sequences computationally. The models predicted interactions involving receptor residues including Ser180, Asn188, Thr272, and Met22; these are computational predictions, not experimentally confirmed binding details.

In in vitro functional assays, the candidate peptide Pep-5 inhibited cAMP accumulation in a manner dependent on CB2 expression, with an EC₅₀ of 6.0 μM. Pep-5 also increased the cAMP-inhibitory effect of the orthosteric agonist WIN55,212-2, consistent with possible positive allosteric modulation. This is an abstract-based summary: the work supports a laboratory candidate and a proposed receptor site, but cannot establish how Pep-5 binds directly, whether it has therapeutic effects, or whether the findings apply in animals or people.

💡 Key Findings

In in vitro assays, Pep-5 inhibited cAMP accumulation in a CB2-expression-dependent manner, with an EC₅₀ of 6.0 μM.

High

80%

Pep-5 increased the cAMP-inhibitory effect of WIN55,212-2, consistent with—but not proof of—positive allosteric modulation.

Good

70%

Computational modeling proposed putative site J as a potential peptide-binding site on CB2; the predicted interactions have not been established as direct binding experimentally in the abstract.

Good

60%

📄 Original Abstract

The cannabinoid receptor type 2 (CB2) is a promising therapeutic target for neuroinflammatory diseases, whereas conventional orthosteric agonists suffer from poor selectivity and metabolic instability. Allosteric modulation, particularly by peptide-based modulators, offers a new strategy to overcome these limitations, yet the molecular mechanisms underlying CB2 allosteric regulation and efficient discovery tools remain lacking. In this study, we computationally investigated the role of the CB2 extracellular putative site J as a predicted binding site for peptide modulators. Using molecular docking and dynamics simulations, we obtained computational insights into the dynamic hydrogen-bonding networks through which the known peptide allosteric modulators Pepcan-12 and osteogenic growth peptide (OGP) are predicted to selectively bind to putative site J in the active-state receptor, with key predicted interacting residues including Ser180, Asn188, Thr272 and Met22. Based on this computational model, we established a flexible docking screening framework targeting putative site J and identified five promising sequences from 56 peptides, among which Pep-5 exhibited the best performance. In vitro functional assays demonstrated that Pep-5 concentration-dependently inhibited cAMP accumulation (EC₅₀ = 6.0 μM) in a manner dependent on CB2 expression. Furthermore, Pep-5 increased the cAMP inhibitory effect of the orthosteric agonist WIN55,212-2, an observation consistent with potential positive allosteric modulation. Through an integrated strategy of "computational mechanistic exploration-rational design-functional validation", this study proposes the putative site J as a potential allosteric site for peptide-based modulation of CB2 and provides candidate peptide Pep-5, offering a new theoretical basis for developing CB2-targeted allosteric drugs.